文献速递消化、代谢与肾脏急症

Olezarsen、急性胰腺炎与家族性乳糜微粒血症综合征

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
PubMed 文献 · N Engl J Med · 2024-04-07
一句话结论在家族性乳糜微粒血症综合征患者中,Olezarsen 80 mg 每4周皮下注射可显著降低甘油三酯水平,并可能减少急性胰腺炎发作。

这项3期双盲安慰剂对照试验纳入66例基因确诊的家族性乳糜微粒血症综合征患者,随机接受Olezarsen 80 mg、50 mg或安慰剂皮下注射每4周一次共49周。主要终点为基线至6个月空腹甘油三酯百分比变化:80 mg组较安慰剂组显著降低43.5个百分点(95%CI -69.1至-17.9,P<0.001),50 mg组降低22.4个百分点未达统计学显著(95%CI -47.2至2.5,P=0.08)。至53周,安慰剂组发生11次急性胰腺炎,两个Olezarsen组合并后各发生1次(率比0.12,95%CI 0.02至0.66)。作者认为Olezarsen可能成为降低家族性乳糜微粒血症综合征患者甘油三酯水平的新疗法。

要点

  • 80 mg Olezarsen每4周皮下注射使6个月空腹甘油三酯较安慰剂组降低43.5个百分点(95%CI -69.1至-17.9,P<0.001)。
  • 50 mg剂量组甘油三酯降低22.4个百分点,未达统计学显著(95%CI -47.2至2.5,P=0.08)。
  • 至53周,安慰剂组发生11次急性胰腺炎,两个Olezarsen组各1次,合并率比0.12(95%CI 0.02至0.66)。
  • 80 mg组载脂蛋白C-III水平较安慰剂组降低73.7个百分点(95%CI -94.6至-52.8),50 mg组降低65.5个百分点(95%CI -82.6至-48.3)。
  • 80 mg组有4例患者发生研究者认为与试验药物相关的中度不良事件。

适用人群与场景

  • 基因确诊的家族性乳糜微粒血症综合征患者;基线平均(±SD)甘油三酯2630±1315 mg/dl,71%在过去10年内有急性胰腺炎病史。

处置流程与药物剂量

  • Olezarsen 80 mg或50 mg皮下注射,每4周一次,共49周。

研究设计与关键结果

  • 3期双盲安慰剂对照试验,66例患者随机分配至Olezarsen 80 mg组(22例)、50 mg组(21例)或安慰剂组(23例)。
  • 主要终点:6个月空腹甘油三酯百分比变化,80 mg组较安慰剂组降低43.5个百分点(95%CI -69.1至-17.9,P<0.001);50 mg组较安慰剂组降低22.4个百分点(95%CI -47.2至2.5,P=0.08)。
  • 关键次要终点:6个月载脂蛋白C-III百分比变化,80 mg组较安慰剂组降低73.7个百分点(95%CI -94.6至-52.8);50 mg组较安慰剂组降低65.5个百分点(95%CI -82.6至-48.3)。
  • 至53周,急性胰腺炎发作:安慰剂组11次,两个Olezarsen组各1次;率比(合并Olezarsen组 vs 安慰剂组)0.12(95%CI 0.02至0.66)。
  • 不良事件:80 mg组有4例患者发生研究者认为与试验药物相关的中度不良事件。

证据类型、等级与局限

  • 证据类型:3期双盲安慰剂对照随机试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于基因确诊的家族性乳糜微粒血症综合征患者,Olezarsen 80 mg每4周皮下注射可能降低甘油三酯水平并可能减少急性胰腺炎发作;50 mg剂量对甘油三酯的降低未达统计学显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.

METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis.

RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group.

CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024. PMID: 38587247. doi:10.1056/NEJMoa2400201

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。